37 results about "Pharmacokinetic modeling" patented technology

The invention discloses a detection control device for anesthetics in blood. The detection control device comprises an anesthetic patient blood receiver (BR). Detection limit and qualitative and quantitative analytical concentration of the blood are detected, analyzed and acquired by the aid of an ion mobility spectrometry (IMS) system or a mass spectrometry (MS) system or an ion mobility spectrometry and mass spectrometry (IMS-MS) combination system, so that the requirement of the human blood on an administration concentration analysis range can be met, and an analytical method for quickly detecting the anesthetics in the blood can be created; analysis results are accurately displayed via a computer software system and include pharmacokinetic models and parameters relevant to medicine infusion; a medical target control infusion (TCI) system can be directly guided by the output results, and hardware of the medical target control infusion system comprises medical infusion pumps, a personal computer (PC) and a safety system mechanism, the infusion pumps can run under the control of the personal computer, and the personal computer can be switched off by the safety system mechanism when the errors occur. The detection control device has the advantages that the detection control device can be used easily and conveniently, is speedy, is high in efficiency and good in reliability, can be automatically controlled, can be widely applied to clinical administration depth analysis and can be used for guiding doctors to accurately apply medicine to the blood in an online manner.

The invention provides an individual drug dosage adjustment method and device. The method comprises steps as follows: the individual feature value of a pharmacokinetic parameter of a designated drug for a patient is determined according to individual information and a group pharmacokinetic model of the designated drug; a time-variable prediction equation of the drug concentration level of the designated drug for the patient is determined according to the individual feature value of the pharmacokinetic parameter of the designated drug for the patient as well as a preset medication plan of the drug; individual dosage adjustment of the designated drug is performed on the patient on the basis of the prediction equation. The concentration of the drug in every patient corresponding to a preset medication plan is accurately predicted according to the individual information of the patient, accordingly, the preset medication plan is adjusted according to a prediction result, and risks caused by adjustment afterwards are avoided.

The present invention concerns the optimization of hiv-1 therapy using the combination of a bioanalytical method, population pharmacokinetic models and phenotypic resistance testing.

The invention provides a construction method of a kidney transplantation anti-infection drug dosage prediction model. The method comprises the following steps: establishing a group pharmacokinetic model of an anti-infective drug by adopting a nonlinear mixed effect model, a two-atrioventricular model and a mixed residual model through plasma concentration analysis, and calculating pharmacokinetic parameters of the corresponding model; and carrying out related hypothesis testing and estimation on the obtained model pharmacokinetic parameters based on a bootstrap method, visual prediction testing and normalized prediction distribution errors, and completing the steps of stability and prediction capability evaluation and the like. According to the established pharmacokinetic model of the kidney transplantation patient population, the reasonable judgment on the medication scheme information is accurately realized, the reference of the optimal dosage is expected to be provided in the infection prevention and treatment process, the adverse reaction risk is reduced, the curative effect is improved, and finally the individualized administration of the anti-infection medicine of the kidney transplantation patient is realized.

A system includes a parameter generation system to determine at least one parameter for an injection procedure (for example, a parameter of an injection protocol or an imaging system parameter), the parameter generator system includes a physiologically based pharmacokinetic model to model propagation of a contrast medium injected into a patient including at least one of a non-linear saturation term in a peripheral venous compartment, at least one configurable transport delay term through at least one compartment, or an adaptation to model volumetric flow rate of blood and an effect thereof on the propagation of contrast medium after injection of contrast medium ceases. The physiologically based pharmacokinetic model can, for example, be discretizable.

The present invention discloses a method for extracting AIF and an application thereof to DCE-MRI. The method comprises steps: contacting a target tissue with a contrast agent to obtain a plurality of images; using the plurality of images to work out the tissue concentration curve of the contrast agent in each voxel; calculating the purity of the tissue concentration curve of each voxel according to the tissue concentration curves; and extracting the voxel having the highest purity as the optimized arterial location; and extracting the tissue concentration curve of the voxel having the highest purity as the arterial input function. The extracted AIF is applied to a pharmacokinetic model to obtain associated pharmacokinetic parameters. The present invention not only improves the accuracy and reliability of the derived quantitative indexes but also promotes the efficiency of the quantitative analysis.

The invention relates to the field of biomedicines, in particular to a method for inducing differentiation of stem cells into islet-like cells in vitro and use of islet-like cells. The invention aims to provide a method for obtaining a large amount of islet-like cells in vitro and the use of the islet-like cells differentiated under induction as seed cells in transplantation of islet cells and preparation of microencapsulated stem cell preparation and as an in-vitro pharmacokinetic model in cell medicine screening. For realizing the aim, the invention adopts a technical scheme that: 1) constructing an NRSF interfering carrier; 2) separating, culturing and amplifying stem cells; 3) inducing stem cells to differentiate into islet-like cells by two stages; and 4) identifying islet-like cells. The construction of the method has a very bright application prospect in regenerative medicine taking gene engineering, cell engineering, tissue engineering and the like as a basis and is expected to create huge social and economic benefit.

A graphical user interface for the documentation of an administered anesthetic drug and the display of an associated pharmacokinetic model and an associated pharmacodynamic model. The graphical user interface comprises a first window that displays the drug administration data, and a second window displaying a pharmacokinetic model and a pharmacodynamic model, the second window being separate and distinct from the first window. The pharmacokinetic model and the pharmacodynamic models are overlaid and displayed and the pharmacokinetic model and the pharmacodynamic model are based on the drug administration data displayed in the first window.

A method of providing a pharmacokinetic model to provide optimize pharmacokinetic data associated with administering a drug to a patient and a method of optimising pharmacokinetic data associated with administering a drug to a patient, data processing apparatus, recording medium and a pharmacokinetic model are disclosed.

There are provided a system and a method therefor for analyzing pharmacokinetics in such a manner that the influence of genetic polymorphism of an individual is taken into consideration, and a system and a method therefor for allowing implementation of high-accuracy haplotype frequency estimation and diplotype configuration estimation even in a case where the number of individuals is small from which data is obtainable when making pharmacokinetic analysis. A diplotype configuration estimation step estimates diplotype configurations of individuals. Next, a pharmacokinetic model building step expresses pharmacokinetic parameters as functions of the diplotype configurations of the individuals, thereby configuring pharmacokinetic models. Moreover, a pharmacokinetic parameter estimation step estimates the pharmacokinetic parameters. Here, a diplotype configuration correction step corrects the estimation result of the diplotype configurations of the individuals, thereby implementing an enhancement in the estimation accuracy.

The present invention provides for a simultaneous graphical representation, a risk of bleeding and a risk of thrombosis providing a visualized bridge therapy process. Furthermore, the present invention provides for a computer-based prediction of the haemostatic situation of the examined blood circulation by using a combination of a biochemical model and a pharmacokinetic model for calculation or another mathematical representation of the blood circulation.

The invention relates to a Dynamic parameter determination method and device, computer equipment and A storage medium. The method comprises the following steps: acquiring at least two groups of scanning data of a target area, wherein time information corresponding to the at least two groups of scanning data is different; inputting the at least two groups of scanning data into a trained analysis model to obtain a region of interest of the target region; determining values of kinetic parameters on the basis of the region of interest and a pharmacokinetic model, the kinetic parameters being related to the metabolic information of the tracer agent in the target region; and reconstructing a dynamic parameter image based on the at least two pieces of scanning data and the value of the kinetic parameter. By adopting the method, the efficiency of acquiring the PET kinetic parameters can be improved.

The invention relates to a method for building a population pharmacokinetics model of multiple components of compound salvia miltiorrhiza drop pills in rats. The method comprises the following steps of: (1) determining sampling point time: grouping sampling points at random on the basis of holographic sampling, with 3-4 sampling points in each group; (2) determining to-be-investigated covariates (the covariates are influence factors): taking physiological and pathological information of rats as the to-be-investigated covariates and investigating the influences of these factors on drug metabolism; (3) incorporating a certain number of tested samples: incorporating the tested samples for the covariates, and confirming that the incorporated samples are uniformly distributed for the covariatesand the test range is relatively wide and meets the later prediction range; (4) carrying out administration, sample acquisition, information collection and sample determination: determining an administration scheme of a compound salvia miltiorrhiza drop pill solution, acquiring blood samples within a predetermined sampling time range, recording corresponding acquisition time, recording individualrelated information for the predetermined covariates and completing sample determination work by using a detection method; and (5) building a model.

A computer system, computer program product and method for determining a probability of attaining a PK-PD target associated with efficacy for a patient that includes a processor obtaining information identifying an infection and based on the information, generating and displaying, by the one or more processors, a list comprising one or more pathogens consistent with the information, the processor then obtaining a first indication designating at least one pathogen from the list comprising one or more pathogens and based on at the obtaining of the least one pathogen, generating a list comprising one or more drug therapies utilized to treat the at least one pathogen. The method also includes the processor obtaining, descriptive information relating to a patient and based on the one or more drug therapies, selecting a pharmacokinetic model and the processor applying the pharmacokinetic model and utilizing the information relating to the patient to determine, for each of the one or more drug therapies, a probability of attaining a PK-PD target associated with efficacy for the patient with the infection.

The invention relates to a method for creating an animal pharmacokinetic model for a drug multi-peak phenomenon. The method includes the following steps: selecting at least 6 dogs with three male dogsand three female dogs, carrying out dosing based on a certain dosage, collecting blood samples after dosing, for a blood sample time point, at least collecting two block sampling points before a first peak, at least collecting three blood sampling points near a highest value of each peak, and at least collecting three blood sampling points after a last peak; measuring the blood drug concentrationby using a liquid mass spectrometer; and calculating a fitting constant (DM) for five types of each dog and indicating a minimum value to be a pharmacokinetic standard model class of the dog. According to the invention, the standard model can be established in the dog, the pharmacokinetic parameters of the drug are calculated correctly, and thus a reasonable dosing plan is provided. The method also can be used for calculating and predicting the drug concentration of the drug in the dog, so that a defect of excessive dog dosing amount due to the small pharmacokinetic parameters of the drug formulti-peak phenomenon calculation by the existing pharmacokinetic software is overcome.

System that automates analysis of mass spectrometry data for oligonucleotides to generate pharmacokinetic parameters and models. A user inputs an oligonucleotide sequence and a maximum number of nucleotides that may be lost during metabolism while retaining therapeutic effectiveness. The system calculates the possible active metabolites and develops a mass spectrum filter for the mass-to-charge ratio of ions for these metabolites. Full-scan spectra are analyzed to calculate the total concentration of these active molecules present in a time series of samples. Pharmacokinetic models and parameters are calculated from the time series of total concentration. Because full-scan spectra are captured, assumptions may be modified and analyses may be quickly rerun without collecting additional data. Overall pharmacokinetic analysis is therefore much more streamlined and efficient, reducing cost, delay, and the need for a mass spectrometrist who is highly skilled in spectral analysis.

A pharmacokinetic analysis method for monitoring therapeutic drugs comprises the following steps: (1) establishing a plasma concentration determination method: establishing the plasma concentration determination method capable of simultaneously monitoring the therapeutic drugs and main metabolites thereof in a plasma sample of a patient by adopting UPLC-MS/MS, and performing methodological verification on the established plasma concentration determination method; (2) establishing a pharmacokinetic model; and (3) monitoring treatment drugs. The pharmacokinetic analysis method for monitoring the therapeutic drug is reasonable in design, provides a basis for individualization of clinical medication of the therapeutic drug by taking the therapeutic drug as a monitoring target, taking blood concentration monitoring as a core and combining pharmacokinetic research data, and provides a basis for clinical medication individualization of the therapeutic drug by monitoring the therapeutic drug for a patient. The curative effect of the treatment medicine can be obviously improved, the occurrence risk of adverse reaction of the treatment medicine is reduced, and the application prospect is wide.